FI115457B - Menetelmä farmaseuttisesti hyväksyttävien 6-kloori-4-trifluorimetyyli-1,4-dihydro-2H-3,1-bentsoksatsin-2-onijohdannaisten valmistamiseksi - Google Patents

Menetelmä farmaseuttisesti hyväksyttävien 6-kloori-4-trifluorimetyyli-1,4-dihydro-2H-3,1-bentsoksatsin-2-onijohdannaisten valmistamiseksi Download PDF

Info

Publication number: FI115457B
Authority: FI; Finland
Prior art keywords: chloro; dihydro; trifluoromethyl; benzoxazin; ethynyl
Prior art date: 1992-08-07

Application number

FI950508A

Other languages

English (en)

Finnish (fi)

Swedish (sv)

Other versions

FI950508A0 (fi

FI950508L (fi

Inventor

Steven D Young

Susan F Britcher

Linda S Payne

Lekhanh O Tran

Jr William C Lumma

Original Assignee

Merck & Co Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-08-07

Filing date

1995-02-06

Publication date

2005-05-13

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26733517&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI115457(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1995-02-06 Application filed by Merck & Co Inc filed Critical Merck & Co Inc

1995-02-06 Publication of FI950508A0 publication Critical patent/FI950508A0/fi

1995-02-06 Publication of FI950508L publication Critical patent/FI950508L/fi

2005-05-13 Application granted granted Critical

2005-05-13 Publication of FI115457B publication Critical patent/FI115457B/fi

Links

238000000034 method Methods 0.000 title claims abstract description 25
238000002360 preparation method Methods 0.000 title claims description 12
230000008569 process Effects 0.000 title claims description 10
150000001875 compounds Chemical class 0.000 claims abstract description 58
150000003839 salts Chemical class 0.000 claims abstract description 10
-1 amino, pyrrolidinyl Chemical group 0.000 claims description 27
RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 12
DRPGAFHTQXUJMY-UHFFFAOYSA-N 6-chloro-4-(2-phenylethynyl)-4-(trifluoromethyl)-1h-3,1-benzoxazin-2-one Chemical compound O1C(=O)NC2=CC=C(Cl)C=C2C1(C(F)(F)F)C#CC1=CC=CC=C1 DRPGAFHTQXUJMY-UHFFFAOYSA-N 0.000 claims description 10
239000003795 chemical substances by application Substances 0.000 claims description 10
125000000217 alkyl group Chemical group 0.000 claims description 8
XPOQHMRABVBWPR-ZDUSSCGKSA-N efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 claims description 8
QKFXVPYWSZJIMC-UHFFFAOYSA-N 6-chloro-4-ethynyl-4-(trifluoromethyl)-1h-3,1-benzoxazin-2-one Chemical compound C1=C(Cl)C=C2C(C(F)(F)F)(C#C)OC(=O)NC2=C1 QKFXVPYWSZJIMC-UHFFFAOYSA-N 0.000 claims description 6
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical group C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 claims description 5
239000003054 catalyst Substances 0.000 claims description 4
FRIJBUGBVQZNTB-UHFFFAOYSA-M magnesium;ethane;bromide Chemical compound [Mg+2].[Br-].[CH2-]C FRIJBUGBVQZNTB-UHFFFAOYSA-M 0.000 claims description 4
NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 claims description 4
KEMUGFRERPPUHB-UHFFFAOYSA-N 2-(2-amino-5-chlorophenyl)-4-cyclopropyl-1,1,1-trifluorobut-3-yn-2-ol Chemical compound NC1=CC=C(Cl)C=C1C(O)(C(F)(F)F)C#CC1CC1 KEMUGFRERPPUHB-UHFFFAOYSA-N 0.000 claims description 3
229930040373 Paraformaldehyde Natural products 0.000 claims description 3
125000000304 alkynyl group Chemical group 0.000 claims description 3
NPTDXPDGUHAFKC-UHFFFAOYSA-N ethynylcyclopropane Chemical group C#CC1CC1 NPTDXPDGUHAFKC-UHFFFAOYSA-N 0.000 claims description 3
238000012986 modification Methods 0.000 claims description 3
230000004048 modification Effects 0.000 claims description 3
229920002866 paraformaldehyde Polymers 0.000 claims description 3
125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 2
125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 2
JDDAFHUEOVUDFJ-UHFFFAOYSA-N 2-iodobenzonitrile Chemical compound IC1=CC=CC=C1C#N JDDAFHUEOVUDFJ-UHFFFAOYSA-N 0.000 claims description 2
GVZVDZMVHZPNBD-UHFFFAOYSA-N 7-(chloromethyl)-1,7-dimethylbicyclo[2.2.1]heptane Chemical group CC1(CCl)C2CCC1(C)CC2 GVZVDZMVHZPNBD-UHFFFAOYSA-N 0.000 claims description 2
239000007818 Grignard reagent Substances 0.000 claims description 2
125000003342 alkenyl group Chemical group 0.000 claims description 2
125000003545 alkoxy group Chemical group 0.000 claims description 2
150000004795 grignard reagents Chemical class 0.000 claims description 2
229910052736 halogen Inorganic materials 0.000 claims description 2
150000002367 halogens Chemical class 0.000 claims description 2
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
YPNCOYLPVNYCMN-UHFFFAOYSA-M magnesium;ethynylcyclopropane;bromide Chemical group [Mg+2].[Br-].[C-]#CC1CC1 YPNCOYLPVNYCMN-UHFFFAOYSA-M 0.000 claims description 2
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
125000000160 oxazolidinyl group Chemical group 0.000 claims description 2
125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 2
125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
238000007363 ring formation reaction Methods 0.000 claims description 2
150000003751 zinc Chemical class 0.000 claims description 2
MJDDHOXHJDDWBP-UHFFFAOYSA-N ethynylcyclopropane Chemical compound [C-]#CC1CC1 MJDDHOXHJDDWBP-UHFFFAOYSA-N 0.000 claims 2
ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 claims 1
QYGIHRYIUSGKGK-UHFFFAOYSA-N 1-ethynyl-4-(trifluoromethyl)-4h-3,1-benzoxazin-2-one Chemical compound C1=CC=C2C(C(F)(F)F)OC(=O)N(C#C)C2=C1 QYGIHRYIUSGKGK-UHFFFAOYSA-N 0.000 claims 1
ZDFAWZFNQFIYGD-UHFFFAOYSA-N 1-methyl-4h-3,1-benzoxazin-2-one Chemical compound C1=CC=C2N(C)C(=O)OCC2=C1 ZDFAWZFNQFIYGD-UHFFFAOYSA-N 0.000 claims 1
RLLFRFBCKFLKNL-UHFFFAOYSA-N 2-[6-chloro-1-ethynyl-2-oxo-4-(trifluoromethyl)-3,1-benzoxazin-4-yl]benzonitrile Chemical compound O1C(=O)N(C#C)C2=CC=C(Cl)C=C2C1(C(F)(F)F)C1=CC=CC=C1C#N RLLFRFBCKFLKNL-UHFFFAOYSA-N 0.000 claims 1
JFKCIAHIGVJPGT-UHFFFAOYSA-N 3-fluoro-2,2-bis(fluoromethyl)propanal Chemical compound FCC(CF)(CF)C=O JFKCIAHIGVJPGT-UHFFFAOYSA-N 0.000 claims 1
ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 claims 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims 1
208000030507 AIDS Diseases 0.000 abstract description 48
238000011282 treatment Methods 0.000 abstract description 21
108010078851 HIV Reverse Transcriptase Proteins 0.000 abstract description 11
239000003443 antiviral agent Substances 0.000 abstract description 9
239000008194 pharmaceutical composition Substances 0.000 abstract description 8
230000002265 prevention Effects 0.000 abstract description 8
208000015181 infectious disease Diseases 0.000 abstract description 7
239000002955 immunomodulating agent Substances 0.000 abstract description 6
229940121354 immunomodulator Drugs 0.000 abstract description 6
230000005764 inhibitory process Effects 0.000 abstract description 5
229960005486 vaccine Drugs 0.000 abstract description 4
239000003242 anti bacterial agent Substances 0.000 abstract description 2
229940088710 antibiotic agent Drugs 0.000 abstract description 2
125000001475 halogen functional group Chemical group 0.000 abstract description 2
239000004615 ingredient Substances 0.000 abstract description 2
HQQTZCPKNZVLFF-UHFFFAOYSA-N 4h-1,2-benzoxazin-3-one Chemical class C1=CC=C2ONC(=O)CC2=C1 HQQTZCPKNZVLFF-UHFFFAOYSA-N 0.000 abstract 1
229940042443 other antivirals in atc Drugs 0.000 abstract 1
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 81
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 66
239000000243 solution Substances 0.000 description 58
239000000203 mixture Substances 0.000 description 29
206010001513 AIDS related complex Diseases 0.000 description 28
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 28
235000019439 ethyl acetate Nutrition 0.000 description 28
HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 27
229960002555 zidovudine Drugs 0.000 description 26
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 24
241000725303 Human immunodeficiency virus Species 0.000 description 24
239000012267 brine Substances 0.000 description 21
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 21
239000002904 solvent Substances 0.000 description 19
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 18
MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 15
238000005160 1H NMR spectroscopy Methods 0.000 description 14
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 14
239000007787 solid Substances 0.000 description 14
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 13
238000001035 drying Methods 0.000 description 13
239000010410 layer Substances 0.000 description 13
208000031886 HIV Infections Diseases 0.000 description 12
229910052786 argon Inorganic materials 0.000 description 12
210000004027 cell Anatomy 0.000 description 12
238000006243 chemical reaction Methods 0.000 description 12
208000037357 HIV infectious disease Diseases 0.000 description 11
238000001914 filtration Methods 0.000 description 11
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 11
239000003112 inhibitor Substances 0.000 description 11
239000000463 material Substances 0.000 description 11
238000003756 stirring Methods 0.000 description 11
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
239000003921 oil Substances 0.000 description 10
239000011541 reaction mixture Substances 0.000 description 10
239000000741 silica gel Substances 0.000 description 10
229910002027 silica gel Inorganic materials 0.000 description 10
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 9
239000013078 crystal Substances 0.000 description 9
XPOQHMRABVBWPR-UHFFFAOYSA-N Efavirenz Natural products O1C(=O)NC2=CC=C(Cl)C=C2C1(C(F)(F)F)C#CC1CC1 XPOQHMRABVBWPR-UHFFFAOYSA-N 0.000 description 8
WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 description 8
239000003814 drug Substances 0.000 description 8
239000012044 organic layer Substances 0.000 description 8
238000003556 assay Methods 0.000 description 7
238000009835 boiling Methods 0.000 description 7
239000000047 product Substances 0.000 description 7
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
238000004587 chromatography analysis Methods 0.000 description 6
229940079593 drug Drugs 0.000 description 6
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 6
229940126601 medicinal product Drugs 0.000 description 6
VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 5
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 5
241000700605 Viruses Species 0.000 description 5
239000000460 chlorine Substances 0.000 description 5
238000001816 cooling Methods 0.000 description 5
239000003480 eluent Substances 0.000 description 5
238000010992 reflux Methods 0.000 description 5
238000003786 synthesis reaction Methods 0.000 description 5
NOKSRMDODJGCPZ-UHFFFAOYSA-N 1-(2-amino-5-chlorophenyl)-2,2,2-trifluoroethanone Chemical compound NC1=CC=C(Cl)C=C1C(=O)C(F)(F)F NOKSRMDODJGCPZ-UHFFFAOYSA-N 0.000 description 4
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
102100031780 Endonuclease Human genes 0.000 description 4
UEXCJVNBTNXOEH-UHFFFAOYSA-N Ethynylbenzene Chemical compound C#CC1=CC=CC=C1 UEXCJVNBTNXOEH-UHFFFAOYSA-N 0.000 description 4
241000713772 Human immunodeficiency virus 1 Species 0.000 description 4
238000005481 NMR spectroscopy Methods 0.000 description 4
206010039491 Sarcoma Diseases 0.000 description 4
230000002924 anti-infective effect Effects 0.000 description 4
230000037396 body weight Effects 0.000 description 4
229910002091 carbon monoxide Inorganic materials 0.000 description 4
239000012678 infectious agent Substances 0.000 description 4
230000002401 inhibitory effect Effects 0.000 description 4
DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 4
IZISMXMXCLUHGI-UHFFFAOYSA-N n-(4-chlorophenyl)-2,2-dimethylpropanamide Chemical compound CC(C)(C)C(=O)NC1=CC=C(Cl)C=C1 IZISMXMXCLUHGI-UHFFFAOYSA-N 0.000 description 4
239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 4
229920006395 saturated elastomer Polymers 0.000 description 4
239000000725 suspension Substances 0.000 description 4
JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 description 3
SENLZSXKQUSKOS-UHFFFAOYSA-N 2-(2-amino-5-chlorophenyl)-1,1,1-trifluorobut-3-yn-2-ol Chemical compound NC1=CC=C(Cl)C=C1C(O)(C#C)C(F)(F)F SENLZSXKQUSKOS-UHFFFAOYSA-N 0.000 description 3
MCWWUWQJNMAMKD-UHFFFAOYSA-N 6-chloro-4-(3-pyrrolidin-1-ylprop-1-ynyl)-4-(trifluoromethyl)-1h-3,1-benzoxazin-2-one Chemical compound O1C(=O)NC2=CC=C(Cl)C=C2C1(C(F)(F)F)C#CCN1CCCC1 MCWWUWQJNMAMKD-UHFFFAOYSA-N 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
206010010071 Coma Diseases 0.000 description 3
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
108010050904 Interferons Proteins 0.000 description 3
102000014150 Interferons Human genes 0.000 description 3
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 3
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
229910052799 carbon Inorganic materials 0.000 description 3
239000012043 crude product Substances 0.000 description 3
239000002274 desiccant Substances 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
239000000284 extract Substances 0.000 description 3
229940079322 interferon Drugs 0.000 description 3
231100000252 nontoxic Toxicity 0.000 description 3
230000003000 nontoxic effect Effects 0.000 description 3
229940127073 nucleoside analogue Drugs 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
108090000623 proteins and genes Proteins 0.000 description 3
238000001953 recrystallisation Methods 0.000 description 3
229910052938 sodium sulfate Inorganic materials 0.000 description 3
235000011152 sodium sulphate Nutrition 0.000 description 3
238000004809 thin layer chromatography Methods 0.000 description 3
238000005406 washing Methods 0.000 description 3
PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
125000004227 1,3-benzoxazol-2-yl group Chemical group [H]C1=C([H])C([H])=C2N=C(*)OC2=C1[H] 0.000 description 2
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
UBDAXLZWFPTBKC-UHFFFAOYSA-N 1-(2-amino-5-chlorophenyl)-2-chloro-2,2-difluoroethanone Chemical compound NC1=CC=C(Cl)C=C1C(=O)C(F)(F)Cl UBDAXLZWFPTBKC-UHFFFAOYSA-N 0.000 description 2
LSGXXXRUQDVIPN-UHFFFAOYSA-N 1-(trifluoromethyl)-4h-3,1-benzoxazin-2-one Chemical compound C1=CC=C2N(C(F)(F)F)C(=O)OCC2=C1 LSGXXXRUQDVIPN-UHFFFAOYSA-N 0.000 description 2
HDMHBHNRWDNNCD-UHFFFAOYSA-N 1-[(2-hydroxyethoxy)methyl]-6-(phenylsulfanyl)thymine Chemical compound OCCOCN1C(=O)NC(=O)C(C)=C1SC1=CC=CC=C1 HDMHBHNRWDNNCD-UHFFFAOYSA-N 0.000 description 2
VTLXWXHOXZCZHC-UHFFFAOYSA-N 2-(2-amino-5-chlorophenyl)-1-chloro-1,1-difluoro-4-phenylbut-3-yn-2-ol Chemical compound NC1=CC=C(Cl)C=C1C(O)(C(F)(F)Cl)C#CC1=CC=CC=C1 VTLXWXHOXZCZHC-UHFFFAOYSA-N 0.000 description 2
QSNSCYSYFYORTR-UHFFFAOYSA-N 4-chloroaniline Chemical compound NC1=CC=C(Cl)C=C1 QSNSCYSYFYORTR-UHFFFAOYSA-N 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
206010012735 Diarrhoea Diseases 0.000 description 2
BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
108010027044 HIV Core Protein p24 Proteins 0.000 description 2
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
206010061218 Inflammation Diseases 0.000 description 2
108010002350 Interleukin-2 Proteins 0.000 description 2
102000000588 Interleukin-2 Human genes 0.000 description 2
208000007766 Kaposi sarcoma Diseases 0.000 description 2
WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
201000009906 Meningitis Diseases 0.000 description 2
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 2
229920000168 Microcrystalline cellulose Polymers 0.000 description 2
IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 2
229910004298 SiO 2 Inorganic materials 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
STSCVKRWJPWALQ-UHFFFAOYSA-N TRIFLUOROACETIC ACID ETHYL ESTER Chemical compound CCOC(=O)C(F)(F)F STSCVKRWJPWALQ-UHFFFAOYSA-N 0.000 description 2
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
235000019270 ammonium chloride Nutrition 0.000 description 2
230000000840 anti-viral effect Effects 0.000 description 2
239000000427 antigen Substances 0.000 description 2
102000036639 antigens Human genes 0.000 description 2
108091007433 antigens Proteins 0.000 description 2
229940121357 antivirals Drugs 0.000 description 2
239000012300 argon atmosphere Substances 0.000 description 2
230000008901 benefit Effects 0.000 description 2
230000005540 biological transmission Effects 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
150000001768 cations Chemical class 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
229910052801 chlorine Inorganic materials 0.000 description 2
229910052681 coesite Inorganic materials 0.000 description 2
229940125782 compound 2 Drugs 0.000 description 2
229910052906 cristobalite Inorganic materials 0.000 description 2
238000002425 crystallisation Methods 0.000 description 2
230000008025 crystallization Effects 0.000 description 2
HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 2
235000005911 diet Nutrition 0.000 description 2
230000037213 diet Effects 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
201000010099 disease Diseases 0.000 description 2
239000002270 dispersing agent Substances 0.000 description 2
230000000694 effects Effects 0.000 description 2
239000003623 enhancer Substances 0.000 description 2
OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 2
238000001704 evaporation Methods 0.000 description 2
230000008020 evaporation Effects 0.000 description 2
239000000945 filler Substances 0.000 description 2
238000003818 flash chromatography Methods 0.000 description 2
239000006260 foam Substances 0.000 description 2
IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 2
125000000623 heterocyclic group Chemical group 0.000 description 2
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 2
238000011534 incubation Methods 0.000 description 2
230000004054 inflammatory process Effects 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
239000011777 magnesium Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
JGZKUKYUQJUUNE-UHFFFAOYSA-L magnesium;ethoxyethane;dibromide Chemical compound [Mg+2].[Br-].[Br-].CCOCC JGZKUKYUQJUUNE-UHFFFAOYSA-L 0.000 description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
239000008108 microcrystalline cellulose Substances 0.000 description 2
229940016286 microcrystalline cellulose Drugs 0.000 description 2
235000019813 microcrystalline cellulose Nutrition 0.000 description 2
ZAHQPTJLOCWVPG-UHFFFAOYSA-N mitoxantrone dihydrochloride Chemical compound Cl.Cl.O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO ZAHQPTJLOCWVPG-UHFFFAOYSA-N 0.000 description 2
239000007922 nasal spray Substances 0.000 description 2
239000002777 nucleoside Substances 0.000 description 2
230000003287 optical effect Effects 0.000 description 2
235000010603 pastilles Nutrition 0.000 description 2
XDRYMKDFEDOLFX-UHFFFAOYSA-N pentamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 XDRYMKDFEDOLFX-UHFFFAOYSA-N 0.000 description 2
229960004448 pentamidine Drugs 0.000 description 2
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
210000001525 retina Anatomy 0.000 description 2
238000002976 reverse transcriptase assay Methods 0.000 description 2
ATEBXHFBFRCZMA-VXTBVIBXSA-N rifabutin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC(=C2N3)C(=O)C=4C(O)=C5C)C)OC)C5=C1C=4C2=NC13CCN(CC(C)C)CC1 ATEBXHFBFRCZMA-VXTBVIBXSA-N 0.000 description 2
239000007858 starting material Substances 0.000 description 2
239000012258 stirred mixture Substances 0.000 description 2
229910052682 stishovite Inorganic materials 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
239000000126 substance Substances 0.000 description 2
125000001424 substituent group Chemical group 0.000 description 2
238000006467 substitution reaction Methods 0.000 description 2
239000000829 suppository Substances 0.000 description 2
239000000375 suspending agent Substances 0.000 description 2
208000011580 syndromic disease Diseases 0.000 description 2
230000002195 synergetic effect Effects 0.000 description 2
229910052905 tridymite Inorganic materials 0.000 description 2
238000001665 trituration Methods 0.000 description 2
102000003390 tumor necrosis factor Human genes 0.000 description 2
GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 1
GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
PISHZENUSKYJSY-UHFFFAOYSA-N 1,1,1-trifluoro-4-phenylbut-3-yn-2-ol Chemical compound FC(F)(F)C(O)C#CC1=CC=CC=C1 PISHZENUSKYJSY-UHFFFAOYSA-N 0.000 description 1
JEIWMMMVZOQQHT-UHFFFAOYSA-N 1,2,2-trimethylcyclopentane-1,3-dicarbonyl chloride Chemical compound CC1(C)C(C(Cl)=O)CCC1(C)C(Cl)=O JEIWMMMVZOQQHT-UHFFFAOYSA-N 0.000 description 1
HQPGKNXCXBJCME-UHFFFAOYSA-N 1,2,3-benzodioxazin-4-one Chemical compound O1ONC(C2=C1C=CC=C2)=O HQPGKNXCXBJCME-UHFFFAOYSA-N 0.000 description 1
YBPWZWXKZDKBLQ-UHFFFAOYSA-N 1-(2-amino-5-chlorophenyl)-3-fluoro-2,2-bis(fluoromethyl)propan-1-one Chemical compound NC1=CC=C(Cl)C=C1C(=O)C(CF)(CF)CF YBPWZWXKZDKBLQ-UHFFFAOYSA-N 0.000 description 1
XKKCQTLDIPIRQD-JGVFFNPUSA-N 1-[(2r,5s)-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)CC1 XKKCQTLDIPIRQD-JGVFFNPUSA-N 0.000 description 1
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
YKBGVTZYEHREMT-KVQBGUIXSA-N 2'-deoxyguanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 YKBGVTZYEHREMT-KVQBGUIXSA-N 0.000 description 1
MAZOKIJIPGIFQC-UHFFFAOYSA-N 2-(2-amino-5-chlorophenyl)-1,1,1-trifluoro-4-phenylbut-3-yn-2-ol Chemical compound NC1=CC=C(Cl)C=C1C(O)(C(F)(F)F)C#CC1=CC=CC=C1 MAZOKIJIPGIFQC-UHFFFAOYSA-N 0.000 description 1
WWIRSVDDUFBDSN-UHFFFAOYSA-N 2-(2-amino-5-chlorophenyl)-1,1,1-trifluorohex-5-en-2-ol Chemical compound NC1=CC=C(Cl)C=C1C(O)(CCC=C)C(F)(F)F WWIRSVDDUFBDSN-UHFFFAOYSA-N 0.000 description 1
LJXGLQWLORNQQY-UHFFFAOYSA-N 2-(4-chloro-2-methylphenoxy)propanoic acid;3,6-dichloro-2-methoxybenzoic acid;n-methylmethanamine Chemical compound CNC.CNC.COC1=C(Cl)C=CC(Cl)=C1C(O)=O.OC(=O)C(C)OC1=CC=C(Cl)C=C1C LJXGLQWLORNQQY-UHFFFAOYSA-N 0.000 description 1
ACTOXUHEUCPTEW-BWHGAVFKSA-N 2-[(4r,5s,6s,7r,9r,10r,11e,13e,16r)-6-[(2s,3r,4r,5s,6r)-5-[(2s,4r,5s,6s)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-10-[(2s,5s,6r)-5-(dimethylamino)-6-methyloxan-2-yl]oxy-4-hydroxy-5-methoxy-9,16-dimethyl-2-o Chemical compound O([C@H]1/C=C/C=C/C[C@@H](C)OC(=O)C[C@@H](O)[C@@H]([C@H]([C@@H](CC=O)C[C@H]1C)O[C@H]1[C@@H]([C@H]([C@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@](C)(O)C2)[C@@H](C)O1)N(C)C)O)OC)[C@@H]1CC[C@H](N(C)C)[C@@H](C)O1 ACTOXUHEUCPTEW-BWHGAVFKSA-N 0.000 description 1
NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 1
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
GZOJTRITAZODJV-UHFFFAOYSA-N 3,1-benzoxazin-2-one Chemical compound C1=CC=CC2=COC(=O)N=C21 GZOJTRITAZODJV-UHFFFAOYSA-N 0.000 description 1
VTSFNCCQCOEPKF-UHFFFAOYSA-N 3-amino-1h-pyridin-2-one Chemical class NC1=CC=CN=C1O VTSFNCCQCOEPKF-UHFFFAOYSA-N 0.000 description 1
SNKAAIQBOBROQQ-UHFFFAOYSA-N 4,7-dimethylbicyclo[2.2.1]heptane-7-carbonyl chloride Chemical compound C1CC2CCC1(C)C2(C)C(Cl)=O SNKAAIQBOBROQQ-UHFFFAOYSA-N 0.000 description 1
YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
DMAYBPBPEUFIHJ-UHFFFAOYSA-N 4-bromobut-1-ene Chemical compound BrCCC=C DMAYBPBPEUFIHJ-UHFFFAOYSA-N 0.000 description 1
QRKPFNCECOOFKA-UHFFFAOYSA-N 4-but-3-enyl-6-chloro-4-(trifluoromethyl)-1h-3,1-benzoxazin-2-one Chemical compound C1=C(Cl)C=C2C(C(F)(F)F)(CCC=C)OC(=O)NC2=C1 QRKPFNCECOOFKA-UHFFFAOYSA-N 0.000 description 1
VJXSSYDSOJBUAV-UHFFFAOYSA-N 6-(2,5-dimethoxy-benzyl)-5-methyl-pyrido[2,3-d]pyrimidine-2,4-diamine Chemical compound COC1=CC=C(OC)C(CC=2C(=C3C(N)=NC(N)=NC3=NC=2)C)=C1 VJXSSYDSOJBUAV-UHFFFAOYSA-N 0.000 description 1
KOYBQLSXOZBCDA-BAJCBRKBSA-N 6-chloro-4-(2-phenylethynyl)-4-(trifluoromethyl)-1-[(4s)-4,7,7-trimethylbicyclo[2.2.1]heptane-3-carbonyl]-3,1-benzoxazin-2-one Chemical compound C1([C@]2(C)CCC(C1)C2(C)C)C(=O)N(C1=CC=C(Cl)C=C11)C(=O)OC1(C(F)(F)F)C#CC1=CC=CC=C1 KOYBQLSXOZBCDA-BAJCBRKBSA-N 0.000 description 1
NIUQFNGWJKYJTM-UHFFFAOYSA-N 6-chloro-4-(trifluoromethyl)-1,4-dihydro-3,1-benzoxazin-2-one Chemical class C1=C(Cl)C=C2C(C(F)(F)F)OC(=O)NC2=C1 NIUQFNGWJKYJTM-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
241000427202 Adria Species 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
241000222122 Candida albicans Species 0.000 description 1
206010007134 Candida infections Diseases 0.000 description 1
101710132601 Capsid protein Proteins 0.000 description 1
108020004635 Complementary DNA Proteins 0.000 description 1
229910021591 Copper(I) chloride Inorganic materials 0.000 description 1
XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
108020004414 DNA Proteins 0.000 description 1
206010012218 Delirium Diseases 0.000 description 1
235000019739 Dicalciumphosphate Nutrition 0.000 description 1
QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
108010042407 Endonucleases Proteins 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
206010017533 Fungal infection Diseases 0.000 description 1
108010010369 HIV Protease Proteins 0.000 description 1
229940122440 HIV protease inhibitor Drugs 0.000 description 1
238000007341 Heck reaction Methods 0.000 description 1
241000282412 Homo Species 0.000 description 1
101100005713 Homo sapiens CD4 gene Proteins 0.000 description 1
108010001584 Human immunodeficiency virus 2 reverse transcriptase Proteins 0.000 description 1
108010054710 IMREG-1 Proteins 0.000 description 1
101150005343 INHA gene Proteins 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
102000006992 Interferon-alpha Human genes 0.000 description 1
108010047761 Interferon-alpha Proteins 0.000 description 1
108010074328 Interferon-gamma Proteins 0.000 description 1
102000008070 Interferon-gamma Human genes 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
238000006683 Mannich reaction Methods 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
229920003091 Methocel™ Polymers 0.000 description 1
208000031888 Mycoses Diseases 0.000 description 1
101000986989 Naja kaouthia Acidic phospholipase A2 CM-II Proteins 0.000 description 1
239000005642 Oleic acid Substances 0.000 description 1
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
108700026244 Open Reading Frames Proteins 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
239000012980 RPMI-1640 medium Substances 0.000 description 1
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
239000004187 Spiramycin Substances 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
235000009470 Theobroma cacao Nutrition 0.000 description 1
101800001703 Thymopentin Proteins 0.000 description 1
102400000160 Thymopentin Human genes 0.000 description 1
ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
206010054094 Tumour necrosis Diseases 0.000 description 1
HIINQLBHPIQYHN-JTQLQIEISA-N Tyr-Gly-Gly Chemical compound OC(=O)CNC(=O)CNC(=O)[C@@H](N)CC1=CC=C(O)C=C1 HIINQLBHPIQYHN-JTQLQIEISA-N 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
XOYXESIZZFUVRD-UVSAJTFZSA-M acemannan Chemical compound CC(=O)O[C@@H]1[C@H](O)[C@@H](OC)O[C@H](CO)[C@H]1O[C@@H]1[C@@H](O)[C@@H](OC(C)=O)[C@H](O[C@@H]2[C@H]([C@@H](OC(C)=O)[C@H](O[C@@H]3[C@H]([C@@H](O)[C@H](O[C@@H]4[C@H]([C@@H](OC(C)=O)[C@H](O[C@@H]5[C@H]([C@@H](OC(C)=O)[C@H](O[C@@H]6[C@H]([C@@H](OC(C)=O)[C@H](O[C@@H]7[C@H]([C@@H](OC(C)=O)[C@H](OC)[C@@H](CO)O7)O)[C@@H](CO)O6)O)[C@H](O5)C([O-])=O)O)[C@@H](CO)O4)O)[C@@H](CO)O3)NC(C)=O)[C@@H](CO)O2)O)[C@@H](CO)O1 XOYXESIZZFUVRD-UVSAJTFZSA-M 0.000 description 1
229960005327 acemannan Drugs 0.000 description 1
229960004150 aciclovir Drugs 0.000 description 1
MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
230000009471 action Effects 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
150000001413 amino acids Chemical group 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
235000011114 ammonium hydroxide Nutrition 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
208000007502 anemia Diseases 0.000 description 1
150000001450 anions Chemical class 0.000 description 1
208000022531 anorexia Diseases 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
150000005130 benzoxazines Chemical class 0.000 description 1
235000019445 benzyl alcohol Nutrition 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
238000001815 biotherapy Methods 0.000 description 1
ACBQROXDOHKANW-UHFFFAOYSA-N bis(4-nitrophenyl) carbonate Chemical compound C1=CC([N+](=O)[O-])=CC=C1OC(=O)OC1=CC=C([N+]([O-])=O)C=C1 ACBQROXDOHKANW-UHFFFAOYSA-N 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
244000309464 bull Species 0.000 description 1
GKPOMITUDGXOSB-UHFFFAOYSA-N but-3-yn-2-ol Chemical compound CC(O)C#C GKPOMITUDGXOSB-UHFFFAOYSA-N 0.000 description 1
244000240602 cacao Species 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
201000003984 candidiasis Diseases 0.000 description 1
DKVNPHBNOWQYFE-UHFFFAOYSA-N carbamodithioic acid Chemical compound NC(S)=S DKVNPHBNOWQYFE-UHFFFAOYSA-N 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical group C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
125000000068 chlorophenyl group Chemical group 0.000 description 1
235000019365 chlortetracycline Nutrition 0.000 description 1
238000011097 chromatography purification Methods 0.000 description 1
229960002227 clindamycin Drugs 0.000 description 1
KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
230000002281 colonystimulating effect Effects 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
230000006957 competitive inhibition Effects 0.000 description 1
229940125773 compound 10 Drugs 0.000 description 1
229940125797 compound 12 Drugs 0.000 description 1
229940125758 compound 15 Drugs 0.000 description 1
229940126214 compound 3 Drugs 0.000 description 1
229940125898 compound 5 Drugs 0.000 description 1
238000009833 condensation Methods 0.000 description 1
230000005494 condensation Effects 0.000 description 1
238000006482 condensation reaction Methods 0.000 description 1
OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 1
229940087451 cytovene Drugs 0.000 description 1
206010061428 decreased appetite Diseases 0.000 description 1
229960000633 dextran sulfate Drugs 0.000 description 1
238000010586 diagram Methods 0.000 description 1
NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
229940038472 dicalcium phosphate Drugs 0.000 description 1
229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
229960002656 didanosine Drugs 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
IEJIGPNLZYLLBP-UHFFFAOYSA-N dimethyl carbonate Chemical compound COC(=O)OC IEJIGPNLZYLLBP-UHFFFAOYSA-N 0.000 description 1
ROORDVPLFPIABK-UHFFFAOYSA-N diphenyl carbonate Chemical compound C=1C=CC=CC=1OC(=O)OC1=CC=CC=C1 ROORDVPLFPIABK-UHFFFAOYSA-N 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000012990 dithiocarbamate Substances 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
239000000890 drug combination Substances 0.000 description 1
238000010828 elution Methods 0.000 description 1
230000010437 erythropoiesis Effects 0.000 description 1
239000012259 ether extract Substances 0.000 description 1
ZKQFHRVKCYFVCN-UHFFFAOYSA-N ethoxyethane;hexane Chemical compound CCOCC.CCCCCC ZKQFHRVKCYFVCN-UHFFFAOYSA-N 0.000 description 1
239000002024 ethyl acetate extract Substances 0.000 description 1
238000003810 ethyl acetate extraction Methods 0.000 description 1
DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
230000029142 excretion Effects 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
229960002963 ganciclovir Drugs 0.000 description 1
230000008570 general process Effects 0.000 description 1
239000003365 glass fiber Substances 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
125000005456 glyceride group Chemical group 0.000 description 1
210000004349 growth plate Anatomy 0.000 description 1
230000036541 health Effects 0.000 description 1
201000002197 heart lymphoma Diseases 0.000 description 1
201000002113 hereditary lymphedema I Diseases 0.000 description 1
239000000833 heterodimer Substances 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
239000004030 hiv protease inhibitor Substances 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
150000002460 imidazoles Chemical class 0.000 description 1
150000003949 imides Chemical class 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
238000003018 immunoassay Methods 0.000 description 1
238000010166 immunofluorescence Methods 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
229960001438 immunostimulant agent Drugs 0.000 description 1
239000003022 immunostimulating agent Substances 0.000 description 1
230000003308 immunostimulating effect Effects 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
238000001802 infusion Methods 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
229950000038 interferon alfa Drugs 0.000 description 1
229960003130 interferon gamma Drugs 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
239000011630 iodine Substances 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
150000002576 ketones Chemical class 0.000 description 1
BWHLPLXXIDYSNW-UHFFFAOYSA-N ketorolac tromethamine Chemical compound OCC(N)(CO)CO.OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 BWHLPLXXIDYSNW-UHFFFAOYSA-N 0.000 description 1
239000008101 lactose Substances 0.000 description 1
229960001375 lactose Drugs 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
GNSLYOGEBCFYDE-UHFFFAOYSA-N lithium;ethynylbenzene Chemical compound [Li+].[C-]#CC1=CC=CC=C1 GNSLYOGEBCFYDE-UHFFFAOYSA-N 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
229940057948 magnesium stearate Drugs 0.000 description 1
229910052943 magnesium sulfate Inorganic materials 0.000 description 1
235000019341 magnesium sulphate Nutrition 0.000 description 1
IBHRUOJKLLUBQG-UHFFFAOYSA-L magnesium;ethene;dibromide Chemical compound [Mg+2].[Br-].[Br-].C=C IBHRUOJKLLUBQG-UHFFFAOYSA-L 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
238000001465 metallisation Methods 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
JMUHBNWAORSSBD-WKYWBUFDSA-N mifamurtide Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)COP(O)(=O)OCCNC(=O)[C@H](C)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1NC(C)=O JMUHBNWAORSSBD-WKYWBUFDSA-N 0.000 description 1
229960005225 mifamurtide Drugs 0.000 description 1
238000002156 mixing Methods 0.000 description 1
UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 1
125000001446 muramyl group Chemical group N[C@@H](C=O)[C@@H](O[C@@H](C(=O)*)C)[C@H](O)[C@H](O)CO 0.000 description 1
SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
231100000344 non-irritating Toxicity 0.000 description 1
239000000346 nonvolatile oil Substances 0.000 description 1
150000003833 nucleoside derivatives Chemical class 0.000 description 1
125000003835 nucleoside group Chemical group 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
229960000988 nystatin Drugs 0.000 description 1
VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
150000002902 organometallic compounds Chemical class 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
IPWFJLQDVFKJDU-UHFFFAOYSA-N pentanamide Chemical compound CCCCC(N)=O IPWFJLQDVFKJDU-UHFFFAOYSA-N 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
210000001428 peripheral nervous system Anatomy 0.000 description 1
102000013415 peroxidase activity proteins Human genes 0.000 description 1
108040007629 peroxidase activity proteins Proteins 0.000 description 1
201000003450 persistent generalized lymphadenopathy Diseases 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
125000004193 piperazinyl group Chemical group 0.000 description 1
229950001030 piritrexim Drugs 0.000 description 1
208000031223 plasma cell leukemia Diseases 0.000 description 1
108700004029 pol Genes Proteins 0.000 description 1
101150088264 pol gene Proteins 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229910000027 potassium carbonate Inorganic materials 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
INDBQLZJXZLFIT-UHFFFAOYSA-N primaquine Chemical compound N1=CC=CC2=CC(OC)=CC(NC(C)CCCN)=C21 INDBQLZJXZLFIT-UHFFFAOYSA-N 0.000 description 1
229960005179 primaquine Drugs 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
125000006239 protecting group Chemical group 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
238000010791 quenching Methods 0.000 description 1
230000000171 quenching effect Effects 0.000 description 1
108700018720 recombinant interferon alpha 2b-like Proteins 0.000 description 1
108010043277 recombinant soluble CD4 Proteins 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000010076 replication Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
229940064914 retrovir Drugs 0.000 description 1
230000001177 retroviral effect Effects 0.000 description 1
238000010839 reverse transcription Methods 0.000 description 1
229960000329 ribavirin Drugs 0.000 description 1
HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
229960000885 rifabutin Drugs 0.000 description 1
238000002390 rotary evaporation Methods 0.000 description 1
238000012216 screening Methods 0.000 description 1
238000007423 screening assay Methods 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
235000012239 silicon dioxide Nutrition 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000000661 sodium alginate Substances 0.000 description 1
235000010413 sodium alginate Nutrition 0.000 description 1
229940005550 sodium alginate Drugs 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
235000017550 sodium carbonate Nutrition 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
235000019372 spiramycin Nutrition 0.000 description 1
229960001294 spiramycin Drugs 0.000 description 1
229930191512 spiramycin Natural products 0.000 description 1
239000007921 spray Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
229940032147 starch Drugs 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
239000007939 sustained release tablet Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
239000003826 tablet Substances 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
PSWFFKRAVBDQEG-YGQNSOCVSA-N thymopentin Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 PSWFFKRAVBDQEG-YGQNSOCVSA-N 0.000 description 1
229960004517 thymopentin Drugs 0.000 description 1
238000004448 titration Methods 0.000 description 1
NOYPYLRCIDNJJB-UHFFFAOYSA-N trimetrexate Chemical compound COC1=C(OC)C(OC)=CC(NCC=2C(=C3C(N)=NC(N)=NC3=CC=2)C)=C1 NOYPYLRCIDNJJB-UHFFFAOYSA-N 0.000 description 1
229960001099 trimetrexate Drugs 0.000 description 1
RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
241001430294 unidentified retrovirus Species 0.000 description 1
230000029812 viral genome replication Effects 0.000 description 1
229940100050 virazole Drugs 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
229960000523 zalcitabine Drugs 0.000 description 1
239000011701 zinc Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
- C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
- C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D265/18—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Virology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Epidemiology (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Molecular Biology (AREA)
Transplantation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Heat Sensitive Colour Forming Recording (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

FI950508A 1992-08-07 1995-02-06 Menetelmä farmaseuttisesti hyväksyttävien 6-kloori-4-trifluorimetyyli-1,4-dihydro-2H-3,1-bentsoksatsin-2-onijohdannaisten valmistamiseksi FI115457B (fi)

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date	Title
US92660792A	1992-08-07	1992-08-07
US92660792		1992-08-07
US5480593A	1993-04-27	1993-04-27
US5480593		1993-04-27
US9307376		1993-08-06
PCT/US1993/007376 WO1994003440A1 (en)	1992-08-07	1993-08-06	Benzoxazinones as inhibitors of hiv reverse transcriptase

Publications (3)

Publication Number	Publication Date
FI950508A0 FI950508A0 (fi)	1995-02-06
FI950508L FI950508L (fi)	1995-02-06
FI115457B true FI115457B (fi)	2005-05-13

Family

ID=26733517

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
FI950508A FI115457B (fi)	1992-08-07	1995-02-06	Menetelmä farmaseuttisesti hyväksyttävien 6-kloori-4-trifluorimetyyli-1,4-dihydro-2H-3,1-bentsoksatsin-2-onijohdannaisten valmistamiseksi
FI20040309A FI20040309A7 (fi)	1992-08-07	2004-02-27	Bentsoksatsinonit HIV-käänteistranskriptaasin estäjinä

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
FI20040309A FI20040309A7 (fi)	1992-08-07	2004-02-27	Bentsoksatsinonit HIV-käänteistranskriptaasin estäjinä

Country Status (36)

Country	Link
EP (1)	EP0582455B1 (zh)
JP (1)	JPH0780860B2 (zh)
KR (1)	KR100272387B1 (zh)
CN (3)	CN1051767C (zh)
AT (1)	ATE197295T1 (zh)
AU (1)	AU670300B2 (zh)
BG (1)	BG62612B1 (zh)
CA (1)	CA2101572C (zh)
CZ (1)	CZ290447B6 (zh)
DE (4)	DE122008000034I1 (zh)
DK (1)	DK0582455T3 (zh)
DZ (1)	DZ1707A1 (zh)
ES (1)	ES2151897T3 (zh)
FI (2)	FI115457B (zh)
GR (1)	GR3034754T3 (zh)
HR (1)	HRP931102B1 (zh)
HU (1)	HU223076B1 (zh)
IL (1)	IL106507A (zh)
LU (2)	LU90709I2 (zh)
LV (1)	LV12719B (zh)
MX (1)	MX192812B (zh)
MY (1)	MY109834A (zh)
NL (2)	NL300032I2 (zh)
NO (3)	NO304886B1 (zh)
NZ (1)	NZ255216A (zh)
PL (2)	PL176679B1 (zh)
PT (1)	PT582455E (zh)
RO (1)	RO113641B1 (zh)
RU (1)	RU2186775C2 (zh)
SG (1)	SG52698A1 (zh)
SI (1)	SI9300419B (zh)
SK (1)	SK282276B6 (zh)
TW (2)	TWI233436B (zh)
UA (1)	UA42699C2 (zh)
WO (1)	WO1994003440A1 (zh)
YU (1)	YU49439B (zh)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5633405A (en) *	1995-05-25	1997-05-27	Merck & Co., Inc.	Asymmetric synthesis of (-)-6-chloro-4-cyclopropyl-ethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxanzin-2-one
US6147210A (en) *	1996-07-26	2000-11-14	Dupont Pharmaceuticals Company	Practical synthesis of benzoxazinones useful as HIV reverse transcriptase inhibitors
AU3736197A (en) *	1996-07-26	1998-02-20	Du Pont Pharmaceuticals Company	A practical synthesis of benzoxazinones useful as hiv reverse transcripta se inhibitors
ZA9711256B (en)	1996-12-16	1999-06-15	Du Pont Merck Pharma	Asymmetric synthesis of benzoxazinones
US5932726A (en) *	1996-12-16	1999-08-03	Dupont Pharmaceuticals Company	Asymmetric synthesis of benzoxazinones
US5965729A (en)	1997-02-05	1999-10-12	Merck & Co., Inc.	Process for the crystallization of a reverse transcriptase inhibitor using an anti-solvent
AU738545C (en) *	1997-02-05	2004-06-17	Merck Sharp & Dohme Corp.	Process for the crystallization of a reverse transcriptase inhibitor using an anti-solvent
EA199900911A1 (ru) *	1997-04-07	2000-04-24	Дюпон Фармасьютикалз Компани	Асимметрический синтез бензоксазинонов через новые промежуточные соединения
US6124302A (en)	1997-04-09	2000-09-26	Dupont Pharmaceuticals	4,4-disubstituted-3,4-dihydro-2(1H)-quinazolinones useful as HIV reverse transcriptase inhibitors
HRP20000120A2 (en) *	1997-09-03	2001-08-31	Merck & Co Inc	Process for enhancing the optical purity of 2r-[1-hydroxy-1-trifluoromethyl-3-cyclopropylpropyn-2yl]-4-chloroaniline
US5952528A (en) *	1997-09-03	1999-09-14	Merck & Co., Inc.	Process for enhancing the optical purity
US20010014352A1 (en)	1998-05-27	2001-08-16	Udit Batra	Compressed tablet formulation
HRP990182A2 (en) *	1998-06-11	2000-02-29	Du Pont Pharm Co	Crystalline efavirenz
US6673372B1 (en)	1998-06-11	2004-01-06	Bristol-Myers Squibb Pharma Company	Crystalline Efavirenz
CA2333643A1 (en) *	1998-06-30	2000-01-06	James D. Rodgers	Substituted quinolin-2(1h)-ones useful as hiv reverse transcriptase inhibitors
US6509334B1 (en)	1999-05-04	2003-01-21	American Home Products Corporation	Cyclocarbamate derivatives as progesterone receptor modulators
SE9904652D0 (sv) *	1999-12-17	1999-12-17	Astra Pharma Prod	Novel Compounds
UA73119C2 (en)	2000-04-19	2005-06-15	American Home Products Corpoir	Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
US6946469B2 (en)	2001-03-28	2005-09-20	Bristol-Myers Squibb Pharma Company	Cyanamide, alkoxyamino, and urea derivatives of 4,4-disubstituted-3,4-dihydro-2(1H)-quinazolinones as HIV reverse transcriptase inhibitors
KR20050119652A (ko)	2003-03-24	2005-12-21	에프. 호프만-라 로슈 아게	역전사 효소 저해제로서의 벤질-피리다진온
AR048650A1 (es) *	2004-05-04	2006-05-10	Tibotec Pharm Ltd	Derivados de (1,10b-dihidro-2-(aminocarbonil-fenil)-5h-pirazolo[1,5 c][1,3]benzoxazin-5-il)fenil metanona como inhibidores de la replicacion viral del vih
TW200710091A (en) *	2005-04-11	2007-03-16	Tibotec Pharm Ltd	(1,10B-dihydro-2-(aminoalkyl-phenyl)-5H-pyrazolo [1,5-c][1,3]benzoxazin-5-yl)phenyl methanone derivatives as HIV viral replication inhibitors
AU2008308092B2 (en) *	2007-10-05	2013-07-11	Msd K.K.	Benzoxazinone derivative
GB0720503D0 (en)	2007-10-22	2007-11-28	Angeletti P Ist Richerche Bio	New compound
EP2448917A2 (de)	2009-07-03	2012-05-09	Archimica GmbH	Verfahren zur enantioselektiven addition von organometallischen kohlenstoffnukleophilen an trifluormethylketone und verwendung des verfahrens in der synthese von hiv reverse transcriptase inhibitoren
SMT201800290T1 (it)	2010-01-27	2018-07-17	Viiv Healthcare Co	Terapia antivirale
EP2471783A1 (en)	2010-12-23	2012-07-04	Esteve Química, S.A.	Novel polymorphic form of efavirenz
CN103664816B (zh) *	2011-01-06	2016-03-02	中国科学院上海有机化学研究所	Hiv逆转录酶抑制剂依法韦伦类化合物的一锅法不对称合成工艺
CN102675125B (zh) *	2011-03-15	2015-02-18	中国科学院上海有机化学研究所	一种4-氯-2-三氟乙酰基苯胺及其类似物的简便高效合成方法
WO2020164218A1 (en)	2019-02-15	2020-08-20	Fujian Yongjing Technology Co., Ltd	New process for friedel-crafts reaction, and catalyst therefore
CN110372625B (zh) *	2019-08-06	2022-11-01	常州大学	蓝光照射制备4-烷甲基-4-芳基-1,3-苯并噁嗪-2(4h)-酮的方法
CN113106473B (zh) *	2021-04-14	2022-02-18	南京工业大学	一种通过连续电化学微反应器装置制备1,3-苯并噁嗪衍生物的方法
EP4416134A4 (en) *	2021-10-15	2025-09-10	Merck Sharp & Dohme Llc	BENZOXAZINONE DERIVATIVES USED AS SELECTIVE CYTOTOXIC AGENTS

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3526621A (en) *	1966-08-03	1970-09-01	Farmaceutical Italia Soc	Substituted 3,1-benzoxazin-2-one
US3562621A (en) *	1967-07-26	1971-02-09	Technipower Inc	Inrush current limiting circuit for rectifier circuits with capacitive load
DE3217012A1 (de) *	1982-05-06	1983-11-10	Dr. Karl Thomae Gmbh, 7950 Biberach	Benzoxazin-2-one, deren herstellung und diese verbindungen enthaltende arzneimittel
CA2032259A1 (en) *	1989-12-18	1991-06-19	Wayne J. Thompson	Hiv protease inhibitors useful for the treatment of aids
IL99843A0 (en) *	1990-11-01	1992-08-18	Merck & Co Inc	Synergistic combination of hiv reverse transcriptase inhibitors

1993
- 1993-07-28 IL IL106507A patent/IL106507A/xx not_active IP Right Cessation
- 1993-07-29 CA CA002101572A patent/CA2101572C/en not_active Expired - Lifetime
- 1993-08-03 DK DK93306114T patent/DK0582455T3/da active
- 1993-08-03 EP EP93306114A patent/EP0582455B1/en not_active Expired - Lifetime
- 1993-08-03 DE DE122008000034C patent/DE122008000034I1/de active Pending
- 1993-08-03 AT AT93306114T patent/ATE197295T1/de active
- 1993-08-03 PT PT93306114T patent/PT582455E/pt unknown
- 1993-08-03 DE DE2001199013 patent/DE10199013I1/de active Pending
- 1993-08-03 DE DE1993629608 patent/DE10199013I2/de active Active
- 1993-08-03 DE DE69329608T patent/DE69329608T2/de not_active Expired - Lifetime
- 1993-08-03 ES ES93306114T patent/ES2151897T3/es not_active Expired - Lifetime
- 1993-08-03 SG SG1996008032A patent/SG52698A1/en unknown
- 1993-08-03 MY MYPI93001523A patent/MY109834A/en unknown
- 1993-08-04 DZ DZ930090A patent/DZ1707A1/fr active
- 1993-08-04 TW TW088117982A patent/TWI233436B/zh not_active IP Right Cessation
- 1993-08-04 TW TW082106237A patent/TW382014B/zh not_active IP Right Cessation
- 1993-08-05 MX MX9304775A patent/MX192812B/es not_active IP Right Cessation
- 1993-08-05 JP JP5194727A patent/JPH0780860B2/ja not_active Expired - Lifetime
- 1993-08-05 YU YU53093A patent/YU49439B/sh unknown
- 1993-08-06 SK SK161-95A patent/SK282276B6/sk active Protection Beyond IP Right Term
- 1993-08-06 UA UA95028099A patent/UA42699C2/uk unknown
- 1993-08-06 NZ NZ255216A patent/NZ255216A/en not_active IP Right Cessation
- 1993-08-06 AU AU44496/93A patent/AU670300B2/en not_active Expired
- 1993-08-06 RO RO95-00190A patent/RO113641B1/ro unknown
- 1993-08-06 SI SI9300419A patent/SI9300419B/sl unknown
- 1993-08-06 KR KR1019950700472A patent/KR100272387B1/ko not_active Expired - Lifetime
- 1993-08-06 HR HR931102A patent/HRP931102B1/xx not_active IP Right Cessation
- 1993-08-06 RU RU95107403/04A patent/RU2186775C2/ru active
- 1993-08-06 PL PL93325950A patent/PL176679B1/pl unknown
- 1993-08-06 WO PCT/US1993/007376 patent/WO1994003440A1/en not_active Ceased
- 1993-08-06 PL PL93307348A patent/PL175615B1/pl unknown
- 1993-08-06 HU HU9500366A patent/HU223076B1/hu active Protection Beyond IP Right Term
- 1993-08-06 CN CN93117660A patent/CN1051767C/zh not_active Expired - Lifetime
- 1993-08-06 CZ CZ1995286A patent/CZ290447B6/cs not_active IP Right Cessation
- 1993-08-06 CN CNB991181085A patent/CN1318031C/zh not_active Expired - Lifetime
1995
- 1995-01-30 BG BG99383A patent/BG62612B1/bg unknown
- 1995-02-06 NO NO950424A patent/NO304886B1/no active Protection Beyond IP Right Term
- 1995-02-06 FI FI950508A patent/FI115457B/fi not_active IP Right Cessation
1998
- 1998-10-10 CN CN98121309A patent/CN1107505C/zh not_active Expired - Lifetime
2000
- 2000-06-16 NO NO2000004C patent/NO2000004I1/no unknown
- 2000-11-03 GR GR20000402341T patent/GR3034754T3/el unknown
- 2000-12-08 NL NL300032C patent/NL300032I2/nl unknown
- 2000-12-20 LU LU90709C patent/LU90709I2/fr unknown
2001
- 2001-06-01 LV LVP-01-87A patent/LV12719B/lv unknown
2004
- 2004-02-27 FI FI20040309A patent/FI20040309A7/fi unknown
2008
- 2008-05-15 NL NL300347C patent/NL300347I1/nl unknown
- 2008-05-27 LU LU91446C patent/LU91446I2/fr unknown
- 2008-06-12 NO NO2008008C patent/NO2008008I1/no unknown

Also Published As

Publication number	Publication date
DE122008000034I1 (de)	2008-10-02
PL307348A1 (en)	1995-05-15
HK1009267A1 (zh)	1999-05-28
YU49439B (sh)	2006-03-03
HRP931102A2 (en)	1997-10-31
LV12719A (lv)	2001-09-20
IL106507A (en)	1997-11-20
PL176679B1 (pl)	1999-07-30
IL106507A0 (en)	1993-11-15
PT582455E (pt)	2001-03-30
NO2000004I1 (no)	2000-06-16
ES2151897T3 (es)	2001-01-16
HU223076B1 (hu)	2004-03-01
BG62612B1 (bg)	2000-03-31
CN1318031C (zh)	2007-05-30
KR100272387B1 (ko)	2000-11-15
KR950702970A (ko)	1995-08-23
YU53093A (sh)	1996-10-09
LU91446I2 (fr)	2008-07-28
CZ290447B6 (cs)	2002-07-17
FI20040309A7 (fi)	2004-02-27
RU95107403A (ru)	1996-11-20
RU2186775C2 (ru)	2002-08-10
MX9304775A (es)	1994-05-31
DE69329608D1 (de)	2000-12-07
CN1221608A (zh)	1999-07-07
NO950424L (no)	1995-04-06
NO2008008I1 (no)	2008-06-30
AU4449693A (en)	1994-02-10
AU670300B2 (en)	1996-07-11
CN1107505C (zh)	2003-05-07
HRP931102B1 (en)	2001-06-30
DK0582455T3 (da)	2000-11-27
CN1090277A (zh)	1994-08-03
TWI233436B (en)	2005-06-01
WO1994003440A1 (en)	1994-02-17
ATE197295T1 (de)	2000-11-15
JPH0780860B2 (ja)	1995-08-30
NO304886B1 (no)	1999-03-01
PL175615B1 (pl)	1999-01-29
DE69329608T2 (de)	2001-05-03
SK282276B6 (sk)	2002-01-07
SI9300419A (en)	1994-06-30
EP0582455A1 (en)	1994-02-09
LU90709I2 (fr)	2002-02-04
CZ28695A3 (en)	1995-09-13
HUT71219A (en)	1995-11-28
RO113641B1 (ro)	1998-09-30
UA42699C2 (uk)	2001-11-15
FI950508A0 (fi)	1995-02-06
CN1051767C (zh)	2000-04-26
FI950508L (fi)	1995-02-06
NL300032I2 (nl)	2001-04-02
NO950424D0 (no)	1995-02-06
NL300032I1 (zh)	2001-02-01
DZ1707A1 (fr)	2002-02-17
CA2101572C (en)	2001-08-28
DE10199013I1 (de)	2001-05-23
DE10199013I2 (de)	2007-05-24
MY109834A (en)	1997-08-30
JPH06184124A (ja)	1994-07-05
CN1250652A (zh)	2000-04-19
NZ255216A (en)	1996-05-28
CA2101572A1 (en)	1994-02-08
NL300347I1 (nl)	2008-07-01
MX192812B (es)	1999-07-30
LV12719B (lv)	2001-12-20
TW382014B (en)	2000-02-11
HU9500366D0 (en)	1995-03-28
SG52698A1 (en)	1998-09-28
BG99383A (bg)	1995-09-29
GR3034754T3 (en)	2001-02-28
SI9300419B (sl)	2002-10-31
SK16195A3 (en)	1995-07-11
EP0582455B1 (en)	2000-11-02

Publication	Publication Date	Title
FI115457B (fi)	2005-05-13	Menetelmä farmaseuttisesti hyväksyttävien 6-kloori-4-trifluorimetyyli-1,4-dihydro-2H-3,1-bentsoksatsin-2-onijohdannaisten valmistamiseksi
US5663169A (en)	1997-09-02	Benzoxazinones as inhibitors of HIV reverse transcriptase
WO1995020389A1 (en)	1995-08-03	Benzoxazinones as inhibitors of hiv reverse transcriptase
SK137899A3 (en)	2000-05-16	4,4-disubstituted-3,4-dihydro-2(1h)-quinazolinones useful as hiv reverse transcriptase inhibitors
WO1993004047A1 (en)	1993-03-04	Quinazoline derivatives as inhibitors of hiv reverse transcriptase
HU223565B1 (hu)	2004-09-28	4-Klór-2-[(1-hidroxi-1-trifluormetil-3-ciklopropil)-2-propin-il]-anilin-származékok és aszimmetrikus szintézisük
JP2001505873A (ja)	2001-05-08	Ｈｉｖ逆転写酵素阻害剤として有用な４，４―二置換―１，４―ジヒドロ―２ｈ―３，１―ベンゾオキサジン―２―オン類、およびそれらを製造するための中間体および方法
EP0484071A2 (en)	1992-05-06	Synergism of HIV reverse transcriptase inhibitors
IE912061A1 (en)	1991-12-18	Aminobenzodiazepines
SI9300244A (sl)	1993-12-31	Novi kinazolini kot inhibitorji HIV reverzne transkriptaze
GB2282808A (en)	1995-04-19	3-substituted heterocyclic indoles as inhibitors of HIV reverse transcriptase
CZ289176B6 (cs)	2001-11-14	Farmaceutický prostředek pro inhibici reverzní transkripce HIV
RU2275361C2 (ru)	2006-04-27	Соединение 4-оксохинолина и его применение в качестве ингибитора вич интегразы
HK1009267B (zh)	2001-05-25	苯恶嗪酮用作hiv逆转酶抑制剂

Legal Events

Date	Code	Title	Description
2005-05-13	FG	Patent granted	Ref document number: 115457 Country of ref document: FI
2005-08-17	SPCF	Supplementary protection certificate application filed	Spc suppl protection certif: L20050021
2008-05-16	SPCF	Supplementary protection certificate application filed	Spc suppl protection certif: C20080013
2009-11-06	SPCG	Supplementary protection certificate granted	Spc suppl protection certif: 264 Extension date: 20131120
2010-04-20	PC	Transfer of assignment of patent	Owner name: MERCK SHARP & DOHME CORP. Free format text: MERCK SHARP & DOHME CORP.
2012-08-15	PC	Transfer of assignment of patent	Owner name: MERCK SHARP & DOHME CORP.
2013-02-15	SPCG	Supplementary protection certificate granted	Spc suppl protection certif: C20080013
2013-09-17	MA	Patent expired